Figure 2.

Overall enrichment of ¹³C in analyzed amino acids of untreated control cells and ²¹³Bi-anti-EGFR-MAb treated cells. Results are shown for EJ28-Luc bladder cancer cells (A) and LN18 glioma cells (B). ²¹³Bi-anti-EGFR-MAb treatment of EJ28-Luc cells resulted in a significant decrease of ¹³C-enrichment in alanine, aspartate, glutamate, and serine (***p < 0.0001 compared to controls). Moreover, we observed a slight (nonsignificant = n.s.) decrease in proline. Enrichment of ¹³C varied from 1.6% in proline to 4.5% in alanine (A). In contrast, no significant changes were observed for LN18 cells.